Pharmaceutical

Malaysia approves Antengene’s XPOVIO NDA for multiple myeloma

Antengene received approval from the Malaysian National Pharmaceutical Regulatory Agency for XPOVIO NDA for two multiple myeloma indications.

Aug 7, 2024 - 04:00
Malaysia approves Antengene’s XPOVIO NDA for multiple myeloma
Antengene received approval from the Malaysian National Pharmaceutical Regulatory Agency for XPOVIO NDA for two multiple myeloma indications.
Read the original article

Tags:

Previous Article

FDA grants RPDD to META Pharmaceuticals’ hyperoxaluria drug

Next Article

CVC Capital to pay $925 Million to Mallinckrodt for sale of Therakos Business Unit

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Learning to treat long COVID could help those struggling with chronic fatigue syndrome, too

STAT+: Learning to treat long COVID could help those st...

May 23, 2023

STAT+: FDA advisory panel to debate contentious data on Medtronic’s high blood pressure device

STAT+: FDA advisory panel to debate contentious data on...

Aug 23, 2023

Eli Lilly’s donanemab wins FDA approval for Alzheimer’s disease

Eli Lilly’s donanemab wins FDA approval for Alzheimer’s...

Jul 4, 2024